Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis

Experimental Hematology

Volumn 27, Issue 10, 1999, Pages 1519-1527

  Lickliter, Jason D ^a   Kratzke, Robert A ^c   Nguyen, Phuong L ^b   Niehans, Gloria A ^c   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Blast crisis; Fas ligand; Hematopoietic progenitor cells; Leukemia

Indexed keywords

FAS LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; APOPTOSIS; BLAST CRISIS; BLOTTING, WESTERN; BONE MARROW; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LEUKEMIA, MYELOID, CHRONIC; LYMPH NODES; MEMBRANE GLYCOPROTEINS;

EID: 0032882088     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00091-0     Document Type: Article

References (40)

1. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233.
2. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301.
3. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B.C., Ponstingl H., Krammer P.H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 267:1992;10709.
4. Dhein J., Walczak H., Baumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438.
5. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., Martin S.J., Force W.R., Lynch D.H., Ware C.F., Green D.R. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441.
6. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., Goodwin R.G., Smith C.A., Ramsdell F., Lynch D.H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 181:1995;71.
7. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314.
8. Lynch D.H., Watson M.L., Alderson M.R., Baum P.R., Miller R.E., Tough T., Gibson M., Davis-Smith T., Smith C.A., Hunter K., Bhat D., Din W.et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:1994;131.
9. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y., Strober W., Lenardo M.J., Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935.
10. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol. 4:1997;32.
11. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand. implications for tumor immune escape Science. 274:1996;1363.
12. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med. 184:1996;1075.
13. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007.
14. Shiraki K., Tsuji N., Shioda T., Isselbacher K.J., Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A. 94:1997;6420.
15. Villunger A., Egle A., Marschitz I., Kos M., Bock G., Ludwig H., Geley S., Kofler R., Greil R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells. a potential mechanism of tumor-induced suppression of immune surveillance Blood. 90:1997;12.
16. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., Shanahan F. The Fas counterattack in vivo. apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J Immunol. 160:1998;5669.
17. Mitsiades N., Poulaki V., Kotoula V., Leone A., Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 153:1998;1947.
18. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B., Truitt R.L., Zwaan F.E.et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555.
19. Barrett A.J., Malkovska V. Graft-versus-leukaemia. understanding and using the alloimmune response to treat haematological malignancies Br J Haematol. 93:1996;754.
20. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., Van Rhee F., Mittermueller J.et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 86:1995;2041.
21. Giralt S.A., Kolb H.J. Donor lymphocyte infusions. Curr Opin Oncol. 8:1996;96.
22. Stahnke K., Hecker S., Kohne E., Debatin K.M. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol. 26:1998;844.
23. De Maria R., Testa U., Luchetti L., Zeuner A., Stassi G., Pelosi E., Riccioni R., Felli N., Samoggia P., Peschle C. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 93:1999;796.
24. Traver D., Akashi K., Weissman I.L., Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 9:1998;47.
25. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press.
26. Miller R.T., Estran C. Heat-induced epitope retrieval with a pressure cooker. Suggestions for optimal use Appl Immunohistochem. 3:1995;190.
27. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1995;1777.
28. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 4:1998;31.
29. Hasegawa D., Kojima S., Tatsumi E., Hayakawa A., Kosaka Y., Nakamura H., Sako M., Osugi Y., Nagata S., Sano K. Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood. 91:1998;2793.
30. Van Parijs L., Abbas A.K. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol. 8:1996;355.
31. Raspadori D., Lauria F., Ventura M.A., Rondelli D., Visani G., de Vivo A., Tura S. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia. analysis of 141 cases Leuk Res. 21:1997;603.
32. Vanhaeke D.R., Bene M.C., Garand R., Faure G.C. Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Leuk Lymphoma. 20:1995;137.
33. Lee J., Richburg J.H., Younkin S.C., Boekelheide K. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology. 138:1997;2081.
34. Sung K.J., Paik E.M., Jang K.A., Suh H.S., Choi J.H. Apoptosis is induced by anti-Fas antibody alone in cultured human keratinocytes. J Dermatol. 24:1997;427.
35. Suzuki A., Enari M., Eguchi Y., Matsuzawa A., Nagata S., Tsujimoto Y., Iguchi T. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J. 15:1996;211.
36. Watanabe D., Suda T., Hashimoto H., Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J. 14:1995;12.
37. Beltinger C., Bohler T., Karawajew L., Ludwig W.D., Schrappe M., Debatin K.M. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol. 102:1998;722.
38. Robertson M.J., Manley T.J., Pichert G., Cameron C., Cochran K.J., Levine H., Ritz J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma. 17:1995;51.
39. Traver D., Akashi K., Weissman I.L., Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 9:1998;47.
40. Selleri C., Sato T., Del Vecchio L., Luciano L., Barrett A.J., Rotoli B., Young N.S., Maciejewski J.P. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 89:1997;957.